Patents Assigned to GlaxoSmithKline
-
Patent number: 11969423Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.Type: GrantFiled: August 15, 2018Date of Patent: April 30, 2024Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AGInventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Nicolas Willand
-
Patent number: 11970480Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: GrantFiled: May 17, 2022Date of Patent: April 30, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
-
Publication number: 20240131140Abstract: Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.Type: ApplicationFiled: February 9, 2022Publication date: April 25, 2024Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Babak BAYAT, Véronique HENDERICKX, Bram VUYLSTEKE
-
Publication number: 20240131136Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.Type: ApplicationFiled: November 1, 2023Publication date: April 25, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Elisabeth Marie Monique BERTAUD, Ralph Leon BIEMANS, Nicolas Jean Benoit MONIOTTE, Laurent Bernard Jean STRODIOT
-
Patent number: 11963962Abstract: Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109/L.Type: GrantFiled: August 21, 2019Date of Patent: April 23, 2024Assignee: GLAXOSMITHKLINE LLCInventors: Barbara Jane Klencke, Gregg David Smith, Rafe Michael Joseph Donahue
-
Patent number: 11959092Abstract: The present invention discloses a process for engineering a host cell comprising the steps of; a) integrating a first polynucleotide cassette including a first selection marker flanked by a first pair of recombination sites; b) removing the first selection marker by the action of a recombinase which recognises the first pair of recombination sites; c) integrating a second polynucleotide cassette including a second selection marker flanked by a second pair of recombination sites; and d) removing the second selection marker by the action of a recombinase which recognises the second pair of recombination sites. Also disclosed is a host cell genome polynucleotide comprising a first recombinantly engineered region and a second recombinantly engineered region, wherein a first single recombination site is adjacent to the first recombinantly engineered region, and a second single recombination site is adjacent to the second recombinantly engineered region.Type: GrantFiled: August 7, 2018Date of Patent: April 16, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza Faridmoayer, Michael Thomas Kowarik, Gerd Martin Lipowsky, Fabio Serventi
-
Patent number: 11957749Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.Type: GrantFiled: December 14, 2018Date of Patent: April 16, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Virginia Ammendola, Babak Bayat, Clarisse Lorin, Ventzislav Bojidarov Vassilev, Alessandra Vitelli
-
Publication number: 20240115688Abstract: The present invention is directed to novel, modified FimH polypeptides, nucleic acids encoding them, and the use of the polypeptides and nucleic acids in the treatment and/or prevention of disease, in particular, urinary tract infection (UTI).Type: ApplicationFiled: November 30, 2021Publication date: April 11, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Roberto ADAMO, Roberta COZZI, Adele FANTONI, Sanjay PHOGAT, Roberto ROSINI, Maria SCARSELLI, Newton WAHOME
-
Publication number: 20240115501Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. hese liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.Type: ApplicationFiled: November 14, 2023Publication date: April 11, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew GEALL
-
Patent number: 11951161Abstract: Methods of inducing an immune response comprising at least two administrations of an adjuvanted immunogenic composition, wherein the second administration contains reduced amounts of antigen and adjuvant.Type: GrantFiled: March 11, 2020Date of Patent: April 9, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: William Ripley Ballou, Jr., Arnaud Michel Didierlaurent, Robbert Gerrit Van Der Most
-
Publication number: 20240110926Abstract: The present invention relates to antibiotic agents for use in the treatment of patients presenting with an exacerbation of chronic obstructive pulmonary disease (COPD). More particularly the present invention relates to antibiotic agents for use in the treatment of COPD exacerbations in patients that, through analysis, have been identified as having an increased concentration of the IL-1? and TNF-? cytokine biomarkers in a biological sample taken from said patient. The present invention is further directed to methods of diagnosing and methods of treating a patient presenting with an exacerbation of COPD, said methods including identifying 1 the patient is suffering from an exacerbation that is associated with a bacterial infection.Type: ApplicationFiled: December 15, 2021Publication date: April 4, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Sonia BUDRONI, Simona RONDINI, Silvia ROSSI PACCANI
-
Patent number: 11945826Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.Type: GrantFiled: February 11, 2020Date of Patent: April 2, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Mark Elban, Michal Pawel Glogowski, Michael Clinton Koetting, Brian Griffin Lawhorn, Jay M. Matthews, Jaclyn Renee Patterson
-
Patent number: 11944675Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: October 2, 2020Date of Patent: April 2, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Fabiana Fernandez, Michael Kowarik, Michael Wacker, Michael Wetter
-
Publication number: 20240100140Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: ApplicationFiled: April 6, 2023Publication date: March 28, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza FARIDMOAYER, Rainer FOLLADOR, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Gerd Martin LIPOWSKY, Gerald Johann POSCH, Fabio SERVENTI
-
Patent number: 11939357Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.Type: GrantFiled: June 14, 2021Date of Patent: March 26, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Matthew Bottomley, Vega Masignani
-
Publication number: 20240091338Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.Type: ApplicationFiled: February 28, 2023Publication date: March 21, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alfredo Nicosia, Ricardo Cortese, Alessandra Vitelli
-
Publication number: 20240091345Abstract: The present invention relates to a nucleic acid encoding a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a nucleic acid encoding a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.Type: ApplicationFiled: January 18, 2022Publication date: March 21, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Johann MOLS, Marie TOUSSAINT
-
Publication number: 20240093161Abstract: A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.Type: ApplicationFiled: August 21, 2023Publication date: March 21, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Stefano COLLOCA
-
Patent number: 11932671Abstract: Modified meningococcal fHbp polypeptides with increased stability.Type: GrantFiled: April 30, 2021Date of Patent: March 19, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Matthew Bottomley, Enrico Malito, Manuele Martinelli, Maria Scarselli
-
Patent number: 11932669Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.Type: GrantFiled: April 6, 2021Date of Patent: March 19, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Enrico Malito, Matthew James Bottomley, Andrea Carfi, Sumana Chandramouli, Kate Luisi